Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Technology Diagnoses Pneumonia Caused by Undetected Pathogens

By LabMedica International staff writers
Posted on 11 Oct 2017
A novel next-generation sequencing (NGS) test for respiratory infections has been launched. More...
The test provides a new solution for thousands of physicians who currently experience difficulty in diagnosing and treating patients with pneumonia and other respiratory diseases.

A strategic partnership was developed and commercialized novel infectious disease testing using metagenomics. This hypothesis-free approach to infectious disease testing uses DNA and RNA analysis to quickly identify bacteria, viruses, fungi, and parasites in patient samples.

The test detects more than 200 common and rare bacterial, fungal, and viral respiratory pathogens with a single test. By providing more comprehensive and actionable information within a clinically relevant turnaround time, this testing can help reduce inappropriate antibiotic use, avoid sequential testing, and potentially shorten hospital stays.

Diagnosing patients, particularly critically ill, immunocompromised patients, with suspected pneumonia can potentially require more than a dozen tests (including test panels) to determine the culprit pathogen. The novel test, known as Explify Respiratory, was developed by Arup Laboratories (Salt lake City, UT, USA) and IDbyDNA, Inc (San Francisco, CA, USA). The test is powered by IDbyDNA’s Taxonomer software, a DNA search engine that can rapidly identify any organism by its genetic material. In a study, Explify Respiratory identified pathogens missed by conventional laboratory tests in 44% of immunocompromised children treated in the intensive care unit (ICU) for pneumonia. In 67% of specimens, only one pathogen was detected. Pathogens included 13 bacteria; Klebsiella pneumoniae, Haemophilus influenzae, Staphylococcus aureus; seven fungi; Mucor spp., Fusarium spp., Pneumocystis jirovecii and viruses.

Robert Schlaberg, MD, Dr Med, MPH, a specialist in molecular infectious disease testing, said, “Current diagnostic techniques rely heavily on testing for suspected pathogens, which can be inconclusive and time-consuming. This technology can test for a very large number of pathogens at once, whether they are expected or not. A doctor doesn’t have to suspect the cause of a patient’s infection to direct the test ordering, but can instead simply ask, ‘What is my patient infected with?’” The study was originally presented at the 2017 American Thoracic Society Annual Meeting, held May 19-24, 2017, in Washington, DC, USA.

Related Links:
Arup Laboratories
IDbyDNA

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.